Hans Schambye

CEO at Boost Pharma

Speaker

Hans Schambye is CEO of BOOST Pharma AB, a private biotech company focused on development of an off-the-shelf therapy for osteogenesis imperfect, an orphan indication with a massive unmet medical need. Previously, Hans served as president and CEO of Galecto Inc, a Nasdaq listed biotech company. Hans is a seasoned biotech entrepreneur with extensive experience in drug discovery and development.

Hans served as the Chief Executive Officer of ReceptIcon from 2006 to 2009 and as the CEO of Gastrotech Pharma A/S from 2004 to 2006. Before joining Gastrotech, he was Director of Biology and Pharmacology and Head of Portfolio Management at Maxygen, a US biotech company.

Hans has co-founded several biotech companies, including ProFound Pharma A/S, a Danish biotech company, which was acquired by Maxygen in 2000. Prior to this he had a successful research career at Stanford University and Copenhagen University within the field of receptor biology. Hans is Chairman of DANISH BIO and board member of BII, Tribune Therapeutics and PreTT and he holds an MD from Odense University and a PhD in Medical Sciences from Copenhagen University.